Head and Neck

The following list provides a brief description of head and neck cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.

Decibel

Registered Title	Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DB-020 in Healthy Volunteers
Purpose	This research project is being conducted to investigate the safety, tolerability, and pharmacokinetics of single ascending dose DB-020 when administered via intratympanic injection to healthy adult volunteers.
Lay Summary	N/A
WA Trial Sites	(oncology) Ph. 08 615 26530
Links	Australian and New Zealand Clinical Trials Registry

Acknowledgements: Australian and New Zealand Clinical Trials Registry

INDUCE-3 (GSK 209229)

Registered Title A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Purpose The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as
first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or
metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC). 
Lay Summary  N/A

WA Trial Sites  SCGH Medical Oncology Ph. (08) 6383 3000
Links

US National Library of Medicine

Acknowledgements: US National Library of Medicine

LIBRETTO-531

Registered Title	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Purpose	The purpose for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Lay Summary	N/a
WA Trial Sites	SCGH Medical Oncology Ph. (08) 6383 3000
Links	US National Library of Medicine

Acknowledgements: US National Library of Medicine